In patients with NSCLC [63], monovalent SdAb, bivalent SdAb(Ab) and quadrivalent SdAb were used to inhibit the phosphorylation FAK domain Ty397 of the FAK/Src pathway regulated by CEACAM6, effectively inhibiting EMT-mediated migration and invasion, and the targeting ability of bivalent was superior to that of quadrivalent. Here, CEACAM6 is linked to non-small cell lung carcinoma.